BioSpace News Archive

ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of John Hohneker, M.D. to its Board of Directors.

Fortrea, a leading global contract research organization, announced the appointment of Machelle Sanders to the Company’s Board of Directors.

Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder.

CytomX Therapeutics, Inc. announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.

Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms associated with menopause compared to placebo.

The global single cell analysis market size was evaluated at US$ 3.5 billion in 2023 and is expected to grow at a CAGR of 16.82%, to reach around US$ 16.57 billion by 2033.

HUTCHMED Limited announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760 and tazemetostat, will be presented at the upcoming European Hematology Association Hybrid Congress, taking place on June 13-16, 2024 in Madrid, Spain and online.

Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.